Reference entry · N-terminally modified GHRH(1-44) analog
Tesamorelin
Also known as: TH9507 · Egrifta · GHRH(1-44) analog
- Class
- N-terminally modified GHRH(1-44) analog
- Size
- 44 amino acids
- Primary targets (literature)
- GHRH receptor → pituitary GH / IGF-1 axis
- Regulatory context
- FDA-approved as Egrifta for a specific HIV lipodystrophy indication. RUO catalog tesamorelin is not approved drug product without verified pharmaceutical sourcing.
Overview
Tesamorelin is an FDA-approved GHRH analog studied in phase 3 trials for HIV-associated lipodystrophy with excess visceral adipose tissue. Catalog material is a distinct RUO supply chain from pharmaceutical Egrifta.
Mechanism in research literature
GHRH receptor agonism stimulates pituitary GH release and downstream IGF-1. N-terminal trans-3-hexenoyl modification extends half-life relative to native GHRH(1-44).
Common research focus areas
- Phase 3 VAT reduction in HIV lipodystrophy trials
- Long-term safety and immunogenicity monitoring
- Comparison with shorter GHRH fragments (sermorelin, mod GRF)
- MS identity for 44-mer with N-terminal lipid modification
Full literature roundup
Read the cited research summary
An FDA-approved GHRH(1-44) analog with published phase 3 human data in HIV-associated lipodystrophy. What the clinical literature reports — and how catalog material differs.
Tesamorelin research roundup · 6 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.